Resources

Interview with Dr. John Higgins, M.D., and Steve Freed, Publisher of www.diabetesincontrol.com. John Higgins, MD, Associate Professor, Department of Systems Biology, Harvard Medical School, Department of Pathology, Massachusetts General Hospital.

Job insecurity found to prompt 19% increase in diabetes, myocardial infarction or coronary death risk.

Study focuses on differences in clinical outcomes between initiating glucagon-like peptide-1 receptor agonist (GLP-1 RAs) vs. insulin treatment in patients with type 2 treated with oral glucose-lowering medications (OGLM).

Study finds clinicians less likely to counsel less educated, and younger and older patients.

This oral drug class focuses on the incretin system and its use leads to increased postprandial GLP-1 and G1P levels: 1. Bile Acid sequestrants 2. DPP-4 inhibitors 3. Dopamine-2 agonists 4. Alpha-glucosidase inhibitors Did you get it right? Follow the link to find out!

What do you feel is the primary reason for the high cost of insulin? 1) Greed 2) Research and Development 3) Corporate Salaries 4) Stockholders Needing a Return on Investment 5) Other Follow the link to share your opinion -- and see what others think!

Introducing the new DietSensor app for iOS and Google devices. This App will allow you to scan your food and drinks and get accurate counts to better judge how much insulin to use.

Female, 76 years of age, type 2 diabetes, well managed, A1C 6%, on metformin 500mg daily. Patient also has well-managed hypertension, hyperlipidemia, and osteoporosis. She lives alone. Wants tighter diabetes control. Was having hypoglycemia when on 500mg twice daily. Requests, almost begs me, to increase her medication. States she’s afraid she’s going to have kidney problems.

Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 4 of this Exclusive Interview, is it low carb or is it reduced calories? Dr. Handelsman explains when he recommends one over the other.

In this week's Homerun Slides, the effect of GLP-1 within the human system.